Document is current

Article History

First Online: 5 August 2022

Disclosures

: Daniel V. T. Catenacci, MD reports personal fees for Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Pierian, Silverback Therapeutics, Servier, Blueprint Medicines, Arcus Biosciences, Tempus, Guardant Health, Archer, and Natera. Osmanuddin Ahmed reports advisory board for Johnson and Johnson, Boston Scientific, and Medtronic; speaking fees for Agron Medical, Canon Medical, Philips, and Penumbra; and a research grant from Canon Medical. Sean Pitroda: two patents for methods and kits for diagnosis and triage of patients with colorectal liver metastases are pending. Andy Liao received consultation honoraria for Ispen, Exelixis, Eisai, Genentech, QED Therapeutics, Incyte, Lexicon, BluePrints Medicine, Transthera, and Histosonics Ralph Weichselbaum has stock and other ownership interests with Boost Therapeutics, Immvira LLC, Reflexion Pharmaceuticals, Coordination Pharmaceuticals Inc., Magi Therapeutics, and Oncosenescence. He has served in a consulting or advisory role for Aettis Inc., Astrazeneca, Coordination Pharmaceuticals, Genus, Merck Serono S.A., Nano proteagen, NKMax America Inc, Shuttle Pharmaceuticals, and Highlight Therapeutics, S.L. He has research grants with Varian and Regeneron. He has received compensation including travel, accommodations, or expense reimbursement from Astrazeneca, Boehringer Ingelheim LTD., and Merck Serono S.A. All other authors have no disclosures to declare.